Strontium-89 is a radioactive isotope of the element strontium with a half-life of about 50.5 days. It is used in nuclear medicine for the treatment of bone pain associated with metastatic bone cancer, also known as bone metastases. Strontium-89 is a beta-emitting radioisotope that selectively targets areas of increased bone… Continue Reading…
Rhenium-188 is a radioactive isotope of the element rhenium with a half-life of approximately 17 hours. It is used in nuclear medicine for therapeutic purposes, particularly in the treatment of certain types of cancer. Rhenium-188 is typically used in the form of rhenium-188-labeled compounds, known as radiopharmaceuticals, that can specifically… Continue Reading…
Rhenium-186 is a radioactive isotope of the element rhenium with a half-life of about 3.72 days. It is used in nuclear medicine for therapeutic purposes, particularly in the treatment of certain types of cancer. Rhenium-186 is typically used in the form of rhenium-186-labeled compounds, known as radiopharmaceuticals, that can specifically… Continue Reading…
Phosphorus-32 is a radioactive isotope of the element phosphorus with a half-life of about 14.3 days. It is commonly used in nuclear medicine for both diagnostic and therapeutic purposes. In diagnostic applications, Phosphorus-32 is used as a radioactive tracer in medical imaging studies, such as positron emission tomography (PET) scans.… Continue Reading…
Lutetium-177 is a radioactive isotope of lutetium, a rare earth metal. It is used in targeted radionuclide therapy for the treatment of certain types of cancer, particularly neuroendocrine tumors. Lutetium-177 has a half-life of about 6.7 days, which makes it ideal for medical applications as it decays relatively quickly while… Continue Reading…
Lead-212 is a radioactive isotope of lead that is used in targeted alpha-particle therapy for the treatment of certain types of cancer. It has a half-life of about 10.6 hours, which allows for precise delivery of radiation to cancer cells while minimizing exposure to surrounding healthy tissue. Lead-212 is typically… Continue Reading…
Properties: Iodine-131 (131I) is both a gamma and a beta emitter with a half-life of 8.02 days. The 131I gamma emission (364 keV; 81%) can be used for documentation of the biodistribution of the agent and to calculate a patient-specific dosage to deliver the desired therapeutic radiation dose. The mean… Continue Reading…
Holmium-166 is a radioisotope that is used in the field of nuclear medicine for therapeutic purposes. It is a beta-emitting radioisotope, which means it emits beta particles during radioactive decay. These beta particles have the ability to penetrate tissues and deliver radiation to targeted areas, making Holmium-166 a valuable tool… Continue Reading…
Properties: Copper-67 (67Cu) is a beta-emitting radionuclide with a half-life of 61.8 h. Its main beta emissions take place at 392 keV (57%), at 483 keV (22%) and at 577 keV (20%). 67Cu is also a gamma emitter at 185 keV (45%) and at 93 keV (16%). The mean path… Continue Reading…
Properties and Characteristics Erbium-169 (169Er) is a radioactive isotope that emits both gamma and beta radiation. It has a half-life of approximately 9.4 days, during which it releases gamma rays with an energy of 8 keV (0.16% emission probability) and beta particles at energies of 351 keV (55% intensity) and… Continue Reading…
Although sold through the same channels as radiopharmaceuticals, molecules labeled with cobalt radioisotopes are not used for imaging, but for ex vivo diagnostics. Very small amounts of radiolabeled compounds are injected into patients and organic fluids (e.g., blood and urine samples) are taken at regular intervals for measurements of the… Continue Reading…
Properties: Calcium-47 is an artificial radioactive nuclide of calcium, with a half‐life of 4.54 days. It emits β‐particles of two energy ranges (1,991 and 695 keV) and γ‐radiation at 1,297, 808 and 489 keV and it decays into stable 47Sc. Tenth value layer (TVL) is 17 cm for concrete and… Continue Reading…